Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
HARMONY BIOSCIENCES HOLDINGS, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 32.77 USD | -4.63% | -9.67% | -40.53% | |
| Sep. 27 | Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10 | MT |
| Sep. 26 | North American Morning Briefing: Yield Surge -2- | DJ |
Financials (USD)
| Sales 2023 * | 569 M | Sales 2024 * | 694 M | Capitalization | 1 966 M |
|---|---|---|---|---|---|
| Net income 2023 * | 157 M | Net income 2024 * | 204 M | EV / Sales 2023 * | 2,80x |
| Net cash position 2023 * | 373 M | Net cash position 2024 * | 463 M | EV / Sales 2024 * | 2,17x |
| P/E ratio 2023 * | 13,8x | P/E ratio 2024 * | 10,3x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 58.72% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -4.63% | ||
| 1 week | -9.67% | ||
| 1 month | -9.60% | ||
| 3 months | -6.88% | ||
| 6 months | +0.37% | ||
| Current year | -40.53% |
1 week
32.44
34.83
1 month
32.4439.27
Current year
29.8155.60
1 year
29.8162.09
3 years
25.0962.09
5 years
25.0962.09
10 years
25.0962.09
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 34 M$ | +1.08% | ||
| 0.31% | 25 M$ | +4.63% | - | |
| 0.21% | 70 M$ | -11.83% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 32.77 | -4.63% | 530,582 |
| 23-09-28 | 34.36 | +1.81% | 565,917 |
| 23-09-27 | 33.75 | -0.74% | 521,141 |
| 23-09-26 | 34.00 | +2.63% | 515,683 |
| 23-09-25 | 33.13 | -8.68% | 1,199,778 |
Delayed Quote Nasdaq, September 29, 2023 at 04:00 pm EDT
More quotes
Harmony Biosciences Holdings, Inc. is a commercial-stage, pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The Company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It operates through its subsidiary, Harmony Biosciences, LLC.
Sector
Pharmaceuticals
Calendar
2023-11-15
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
32.77USD
Average target price
57.56USD
Spread / Average Target
+75.63%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -40.53% | 1 966 M $ | |
| +83.43% | 1 229 M $ | |
| -.--% | 90 M $ | |
| +141.94% | 1 689 M $ | |
| +52.60% | 65 M $ | |
| -26.52% | 62 M $ | |
| -36.50% | 69 M $ | |
| -11.04% | 1 249 M $ | |
| +53.49% | 64 M $ | |
| +83.27% | 60 M $ |
